The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 04, 2024

Filed:

Mar. 23, 2020
Applicant:

Immatics Biotechnologies Gmbh, Tuebingen, DE;

Inventors:

Leonie Alten, Tuebingen, DE;

Sebastian Bunk, Tuebingen, DE;

Dominik Maurer, Moessingen, DE;

Claudia Wagner, Tuebingen, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/55 (2017.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/73 (2006.01); C12N 5/00 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
A61K 47/55 (2017.08); A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 39/0011 (2013.01); A61K 39/001186 (2018.08); A61K 47/64 (2017.08); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C12N 5/00 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); A61K 2039/572 (2013.01); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01);
Abstract

The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.


Find Patent Forward Citations

Loading…